Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,165.08
(
0.80%
)
US TECH 100
26,538.40
(
1.85%
)
Dow Jones
49,247.66
(
-0.13%
)
Brent Oil
101.48
(
-0.05%
)
Bitcoin
77,768.05
(
-1.13%
)
News Focus
News Focus
Post# of 347009
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

biopharm

Send PM Follow Ignore
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

biopharm

Re: cjgaddy post# 223044

Wednesday, 07/01/2015 10:51:59 PM

Wednesday, July 01, 2015 10:51:59 PM

Post# of 347009

Sep6-9: IASLC’s 16th World Conf. on Lung Cancer”, Denver wclc2015.iaslc.org
…Peregrine Exhibiting, Booth #1724 (KOL/SAB Dr. David Carbone will be Pres. of IASLC eff. 9-2015)



William D. Travis sits on the BOD at IASLC (2013-2016) so I would say soon to be President at IASLC David Carbone has had many a words with Dr. Travis from Sloan Kettering before Peregrines and MSK's collaboration. Who knows, lots of money and trials are served directly out of IASLC and MSK just may benefit big time from this collaboration.

https://www.iaslc.org/membership/member-directory/william-d-travis

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote